A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast agent for cardiovascular MRI.

摘要: Purpose: To evaluate the imaging potential of ferumoxytol, a new superparamagnetic iron oxide colloidal blood pool contrast agent. Materials and Methods:Magnetic resonance (MR) at 1.5 Tesla was performed before after intravenous injection ferumoxytol using escalating doses 0.4, 0.8, 1.2 1.6 mg Fe/kg for total 4 in five subjects imaged with 3D MR Angiography (MRA) trifurcation each dose. In cardiac cine MRI pre post 4.0 Fe/kg. Image quality assessed by measuring signal to-noise ratio (SNR) contrast-to-noise (CNR) vascular structures. Pre- post-dose urine tests as well EKG/vital sign monitoring were to safety samples collected T1 relaxivity measurements. Results: Cumulative 0, 1.2, 2.4 yielded mean SNR arteries 10, 16, 39, 57 69 respectively indicating that higher produced on images. Similarly aorta 2D time-of-flight increased from 11.8 without Fe 15.4 ( p =0 .004) improved image MRA sequences optimized use contrast. At there substantial shortening measured 1990 ± 573 ms 80 42 p< 0.0001), corresponding SNR. Images large structures including chambers, aorta, pulmonary excellent but images smaller difficult due enhancement overlapping veins. No serious adverse events occurred. Conclusion: The colloid is promising agent especially cardiac, imaging.